Vita Life Sciences (ASX:VLS) Long-Term Debt: A$0.00 Mil (As of Dec. 2025)


ASX:VLS Vita Life Sciences Ltd ASX:VLS
83 GF Score
Price A$2.50
GF Value A$2.48
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Vita Life Sciences Long-Term Debt?

Vita Life Sciences ASX:VLS +2.04% 83 Long-Term Debt is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:VLS with a GF Score™ of 83/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review.

Vita Life Sciences's Long-Term Debt for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Vita Life Sciences's quarterly Long-Term Debt increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$1.76 Mil) but then declined from Jun. 2025 (A$1.76 Mil) to Dec. 2025 (A$0.00 Mil).

Vita Life Sciences  (ASX:VLS) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Vita Life Sciences Long-Term Debt Related Terms

Vita Life Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Vita Life Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vita Life Sciences Long-Term Debt Chart

Vita Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vita Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.13 0.00 1.76 0.00
ASX:VLS
83GF Score
Vita Life Sciences Ltd ASX:VLS
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$0.00 Mil mean?
Vita Life Sciences (ASX:VLS) has a Long-Term Debt of A$0.00 Mil as of Dec. 2025.
Is Vita Life Sciences' Long-Term Debt too high?
Vita Life Sciences' current Long-Term Debt is A$0.00 Mil. Overall, Vita Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Long-Term Debt compare to ZTS and UTHR?
Vita Life Sciences' Long-Term Debt of A$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Vita Life Sciences's current Long-Term Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.50 — trading 0.8% above its estimated fair value. The current Long-Term Debt is A$0.00 Mil. Vita Life Sciences' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Long-Term Debt is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?

Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued. The current stock price of A$2.50 is trading 0.8% above its estimated GF Value™ of A$2.48. GuruFocus considers Vita Life Sciences to be Fairly Valued.

Key valuation signals for ASX:VLS:

  • Long-Term Debt: A$0.00 Mil
  • GF Value™: A$2.48 vs. price of A$2.50 (0.8% above fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vita Life Sciences Business Description

Address 1-5 Chalmers Crescent, Suite 802, Level 8, Mascot, Sydney, NSW, AUS, 2020
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
83GF Score

Get the complete analysis for ASX:VLS

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.50
Price
A$2.48
GF Value